Viridian Therapeutics Stock Soars on Positive Phase III Veligrotug Trial Results for Chronic Thyroid Eye Disease
Veligrotug’s Phase III trial shows significant improvement in chronic thyroid eye disease (TED) symptoms like proptosis and diplopia. The positive results suggest veligrotug could be a new treatment option for TED patients.